METHODS OF DRUG THERAPY SELECTION FOR BREAST CANCER PATIENTS BASED ON HER2 AND HER3 PATHWAY SUBTYPING

• Main Authors: LANGLEY EMMA, KIM PHILLIP, MICHEL JOSEPH
• Format: Patent
• Language: Chinese; English
• Published: 21.05.2019
• Subjects: CHEMISTRY; COMBINATORIAL CHEMISTRY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICOLIBRARIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; TESTING

Provided herein is a method for determining whether a human subject with breast cancer will respond to a therapy comprising a tyrosine kinase inhibitor or a biologic. The method includes determining the expression level and/or activation level of various signal transduction molecules such as truncated HER2 protein, full-length HER2 protein, HER3 protein, PI3K protein, and others. The determinationof likely response to a tyrosine kinase inhibitor therapy or a biologic therapy involves comparing the expression level and/or activation level of the signal transduction molecule(s) to a reference expression/activation level for the specific signal transduction molecule(s). 本文提供了用于确定患有乳癌的人受试者是否将对包含酪氨酸激酶抑制剂或生物制剂的疗法反应的方法。该方法包括测定各种信号转导分子的表达水平和/或活化水平，所述信号转导分子如截短HER2蛋白、全长HER2蛋白、HER3蛋白、PI3K蛋白等。确定对酪氨酸激酶抑制剂疗法或生物制剂疗法反应的可能性包括比较一种或多种信号转导分子的表达水平和/或活化水平与一种或多种特定信号转导分子的参考表达/活化水平。